Cargando…
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
AIMS: To evaluate the safety, pharmacokinetics and pharmacodynamics of single‐ and multiple‐rising doses (MRDs) of BI 705564 and establish proof of mechanism. METHODS: BI 705564 was studied in 2 placebo‐controlled, Phase I clinical trials testing single‐rising doses (1–160 mg) and MRDs (1–80 mg) of...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290462/ https://www.ncbi.nlm.nih.gov/pubmed/32986868 http://dx.doi.org/10.1111/bcp.14571 |
_version_ | 1784748905864364032 |
---|---|
author | Litzenburger, Tobias Steffgen, Jürgen Benediktus, Ewald Müller, Fabian Schultz, Armin Klein, Elliott Ramanujam, Meera Harcken, Christian Gupta, Alpana Wu, Jing Wiebe, Sabrina Li, Xiujiang Flack, Mary Padula, Steven J. Visvanathan, Sudha Hünnemeyer, Andreas Hui, Jianan |
author_facet | Litzenburger, Tobias Steffgen, Jürgen Benediktus, Ewald Müller, Fabian Schultz, Armin Klein, Elliott Ramanujam, Meera Harcken, Christian Gupta, Alpana Wu, Jing Wiebe, Sabrina Li, Xiujiang Flack, Mary Padula, Steven J. Visvanathan, Sudha Hünnemeyer, Andreas Hui, Jianan |
author_sort | Litzenburger, Tobias |
collection | PubMed |
description | AIMS: To evaluate the safety, pharmacokinetics and pharmacodynamics of single‐ and multiple‐rising doses (MRDs) of BI 705564 and establish proof of mechanism. METHODS: BI 705564 was studied in 2 placebo‐controlled, Phase I clinical trials testing single‐rising doses (1–160 mg) and MRDs (1–80 mg) of BI 705564 over 14 days in healthy male volunteers. Blood samples were analysed for BI 705564 plasma concentration, Bruton's tyrosine kinase (BTK) target occupancy (TO) and CD69 expression in B cells stimulated ex vivo. A substudy was conducted in allergic, otherwise healthy, MRD participants. Safety was assessed in both studies. RESULTS: All doses of BI 705564 were well tolerated. Geometric mean BI 705564 plasma terminal half‐life ranged from 10.1 to 16.9 hours across tested doses, with no relevant accumulation after multiple dosing. Doses ≥20 mg resulted in ≥85% average TO that was maintained for ≥48 hours after single‐dose administration. Functional effects of BTK signalling were demonstrated by dose‐dependent inhibition of CD69 expression. In allergic participants, BI 705564 treatment showed a trend in wheal size reduction in a skin prick test and complete inhibition of basophil activation. Mild bleeding‐related adverse events were observed with BI 705564; bleeding time increased in 1/12 participants (8.3%) who received placebo vs 26/48 (54.2%) treated with BI 705564. CONCLUSION: BI 705564 showed efficient target engagement through durable TO and inhibition of ex vivo B‐cell activation, and proof of mechanism through effects on allergic skin responses. Mild bleeding‐related adverse events were probably related to inhibition of platelet aggregation by BTK inhibition. |
format | Online Article Text |
id | pubmed-9290462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92904622022-07-20 Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers Litzenburger, Tobias Steffgen, Jürgen Benediktus, Ewald Müller, Fabian Schultz, Armin Klein, Elliott Ramanujam, Meera Harcken, Christian Gupta, Alpana Wu, Jing Wiebe, Sabrina Li, Xiujiang Flack, Mary Padula, Steven J. Visvanathan, Sudha Hünnemeyer, Andreas Hui, Jianan Br J Clin Pharmacol Original Articles AIMS: To evaluate the safety, pharmacokinetics and pharmacodynamics of single‐ and multiple‐rising doses (MRDs) of BI 705564 and establish proof of mechanism. METHODS: BI 705564 was studied in 2 placebo‐controlled, Phase I clinical trials testing single‐rising doses (1–160 mg) and MRDs (1–80 mg) of BI 705564 over 14 days in healthy male volunteers. Blood samples were analysed for BI 705564 plasma concentration, Bruton's tyrosine kinase (BTK) target occupancy (TO) and CD69 expression in B cells stimulated ex vivo. A substudy was conducted in allergic, otherwise healthy, MRD participants. Safety was assessed in both studies. RESULTS: All doses of BI 705564 were well tolerated. Geometric mean BI 705564 plasma terminal half‐life ranged from 10.1 to 16.9 hours across tested doses, with no relevant accumulation after multiple dosing. Doses ≥20 mg resulted in ≥85% average TO that was maintained for ≥48 hours after single‐dose administration. Functional effects of BTK signalling were demonstrated by dose‐dependent inhibition of CD69 expression. In allergic participants, BI 705564 treatment showed a trend in wheal size reduction in a skin prick test and complete inhibition of basophil activation. Mild bleeding‐related adverse events were observed with BI 705564; bleeding time increased in 1/12 participants (8.3%) who received placebo vs 26/48 (54.2%) treated with BI 705564. CONCLUSION: BI 705564 showed efficient target engagement through durable TO and inhibition of ex vivo B‐cell activation, and proof of mechanism through effects on allergic skin responses. Mild bleeding‐related adverse events were probably related to inhibition of platelet aggregation by BTK inhibition. John Wiley and Sons Inc. 2020-11-20 2021-04 /pmc/articles/PMC9290462/ /pubmed/32986868 http://dx.doi.org/10.1111/bcp.14571 Text en © 2020 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Litzenburger, Tobias Steffgen, Jürgen Benediktus, Ewald Müller, Fabian Schultz, Armin Klein, Elliott Ramanujam, Meera Harcken, Christian Gupta, Alpana Wu, Jing Wiebe, Sabrina Li, Xiujiang Flack, Mary Padula, Steven J. Visvanathan, Sudha Hünnemeyer, Andreas Hui, Jianan Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title | Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title_full | Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title_fullStr | Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title_full_unstemmed | Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title_short | Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers |
title_sort | safety, pharmacokinetics and pharmacodynamics of bi 705564, a highly selective, covalent inhibitor of bruton's tyrosine kinase, in phase i clinical trials in healthy volunteers |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290462/ https://www.ncbi.nlm.nih.gov/pubmed/32986868 http://dx.doi.org/10.1111/bcp.14571 |
work_keys_str_mv | AT litzenburgertobias safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT steffgenjurgen safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT benediktusewald safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT mullerfabian safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT schultzarmin safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT kleinelliott safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT ramanujammeera safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT harckenchristian safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT guptaalpana safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT wujing safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT wiebesabrina safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT lixiujiang safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT flackmary safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT padulastevenj safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT visvanathansudha safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT hunnemeyerandreas safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers AT huijianan safetypharmacokineticsandpharmacodynamicsofbi705564ahighlyselectivecovalentinhibitorofbrutonstyrosinekinaseinphaseiclinicaltrialsinhealthyvolunteers |